Phase II RCT to Assess Efficacy of Intravenous Administration of Oxytocin in Patients Affected by COVID-19

NCT04386447 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped The study was not approved by the Italian Medicines Agency (AIFA).

Conditions

Covid-19
Corona Virus Infection
SARS-CoV 2

Interventions

DRUG: Oxytocin
DRUG: Standard of Care

Sponsor

Azienda Ospedaliero-Universitaria di Parma

Collaborators

[object Object]